Small molecule inhibitors of oncogenic MIR-21
Ended Project Grant Awarded Last action
- Award ID
- R41CA254746
- Recipient
-
Ithax Pharmaceuticals Inc. UEI D6ZLMK2SMHJ5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $249,109
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Shoreline, WA 98133, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $249,109 |
Quick answers
Who received award R41CA254746?
R41CA254746 was awarded to Ithax Pharmaceuticals Inc. by National Cancer Institute (National Institutes of Health) on August 14, 2020.
How much is award R41CA254746 worth?
$249,109 has been obligated on R41CA254746.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award